{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:12:37Z","timestamp":1793103157896,"version":"4.5.0"},"reference-count":16,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Valneva","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Pfizer Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Lyme disease (LD) is the most frequent tick-borne disease in the moderate climates of Europe. This study will inform the phase III efficacy study for Pfizer and Valneva\u2019s investigational Lyme disease vaccine, VLA15. VLA15 phase III will be conducted in the USA and Europe due to the vaccine\u2019s serotype coverage and public health burden of LD. In Europe, the existence and location of sites that have access to populations with high LD annual incidence is uncertain. This active, prospective surveillance study assesses annual LD incidence at general practice (GP)\/primary care sites, allowing for phase III site vetting and better characterisation of LD burden in selected regions for study size calculations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>This burden of Lyme disease (BOLD) study will assess LD incidence overall and by site at 15 GP\/primary care practices in endemic areas of 6 European countries from Spring 2021 to December 2022 and will be summarised with counts (n), percentages (%) and associated 95% CIs. Suspected LD cases identified from site\u2019s practice panels are documented on screening logs, where clinical LD manifestations, diagnoses and standard of care diagnostic results are recorded. In the initial 12-month enrolment phase, suspected LD cases are offered enrolment. Participants undergo interview and clinical assessments to establish medical history, final clinical diagnosis, clinical manifestations and quality of life impact. Study-specific procedures include LD serology, skin punch biopsies and Lyme manifestation photographs. For every enrolled participant diagnosed with LD, 6\u201310 age-matched controls are randomly selected and offered enrolment for an embedded LD risk factor analysis. Persistent symptoms or post-treatment LD will be assessed at follow-up visits up to 2\u2009years after initial diagnosis, while patients remain symptomatic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>This study has been approved by all sites\u2019 local ethics committees. The results will be presented at conferences and published in peer-reviewed journals.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-070903","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T16:28:37Z","timestamp":1702225717000},"page":"e070903","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Prospective incidence epidemiology study protocol: conducting active surveillance to assess the burden of Lyme disease (BOLD) in primary care practices in endemic areas of six European countries"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-5416","authenticated-orcid":false,"given":"Elizabeth","family":"Begier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2924-0836","authenticated-orcid":false,"given":"Alexandra","family":"Loew-Baselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Bowdery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Halsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendwas","family":"Dzingina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"B\u00e9zay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Parslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-7194","authenticated-orcid":false,"given":"Bradford D","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,10]]},"reference":[{"key":"2023121221174598000_13.12.e070903.1","unstructured":"Lindgren E , Jaenson TGT . Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. WHO, Regional Office for Europe, 2006."},{"key":"2023121221174598000_13.12.e070903.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03175.x"},{"key":"2023121221174598000_13.12.e070903.3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ttbdis.2011.04.002","article-title":"Updates on Borrelia Burgdorferi Sensu Lato complex with respect to public health","volume":"2","author":"Rudenko","year":"2011","journal-title":"Ticks and Tick-Borne Diseases"},{"key":"2023121221174598000_13.12.e070903.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807233390401"},{"key":"2023121221174598000_13.12.e070903.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807233390402"},{"key":"2023121221174598000_13.12.e070903.6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/vbz.2022.0071","article-title":"Incidence of Lyme Borreliosis in Europe from national surveillance systems (2005\u20132020)","volume":"23","author":"Burn","year":"2023","journal-title":"Vector-Borne and Zoonotic Diseases"},{"key":"2023121221174598000_13.12.e070903.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2007.05.002"},{"key":"2023121221174598000_13.12.e070903.8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(18)31738-0","article-title":"Introducing EU-wide surveillance of Lyme Neuroborreliosis","volume":"392","year":"2018","journal-title":"The Lancet"},{"key":"2023121221174598000_13.12.e070903.9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1089\/vbz.2022.0070","article-title":"Incidence of Lyme Borreliosis in Europe: A systematic review (2005 -2020)","volume":"23","author":"Burn","year":"2023","journal-title":"Vector-Borne and Zoonotic Diseases"},{"key":"2023121221174598000_13.12.e070903.10","doi-asserted-by":"crossref","unstructured":"Vrijmoeth HD , Ursinus J , Harms MG , et al . Prevalence and determinants of persistent symptoms after treatment for Lyme Borreliosis: study protocol for an observational, prospective cohort study (Lymeprospect). BMC Infect Dis 2019;19. doi:10.1186\/s12879-019-3949-8 Available: https:\/\/doi.org\/10.1186\/s12879-019-3949-8","DOI":"10.1186\/s12879-019-3949-8"},{"key":"2023121221174598000_13.12.e070903.11","doi-asserted-by":"publisher","DOI":"10.1086\/508667"},{"key":"2023121221174598000_13.12.e070903.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2013.01.008"},{"key":"2023121221174598000_13.12.e070903.13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fmed.2020.00057","article-title":"Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease","volume":"7","author":"Rebman","year":"2020","journal-title":"Front Med"},{"key":"2023121221174598000_13.12.e070903.14","first-page":"741","article-title":"European Union concerted action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis","volume":"108","author":"Stanek","year":"1996","journal-title":"Wien Klin Wochenschr"},{"key":"2023121221174598000_13.12.e070903.15","unstructured":"Maruish ME , ed. User\u2019s manual for the SF-36v2 Health Survey . 3rd ed. Lincoln, RI: QualityMetric Incorporated."},{"key":"2023121221174598000_13.12.e070903.16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12879-019-3949-8","article-title":"Prevalence and determinants of persistent symptoms after treatment for Lyme Borreliosis: study protocol for an observational, prospective cohort study (Lymeprospect)","volume":"19","author":"Vrijmoeth","year":"2019","journal-title":"BMC Infect Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-070903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T05:20:22Z","timestamp":1702444822000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-070903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,10]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bmjopen-2022-070903"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-070903","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}